Table 3 Proportions with virological failure, non-resistance, and second line switch, by strategy (1000-patient Markov cohort analysis)
Strategy | Proportion of cohort with virological failure | Proportion of virological failures identified as non-resistant | Proportion of cohort switched to second-line therapy |
|---|---|---|---|
Routine monitoring (RM) | 19.8% | 0.0% | 19.8% |
Resistance testing (RT) | 20.2% | 16.8% | 16.7% |
Limited testing (LT) | 20.2% | 11.4% | 17.8% |